Ewopharma to market anti-TNF biosimilars in Central Eastern Europe
Privately-held Swiss firm Ewopharma has signed an agreement to market and sell anti-tumor necrosis factor (anti-TNF) biosimilars of Enbrel (etanercept) and Remicade (infliximab) in Central Eastern Europe.
The originator drugs are from US pharma majors Pfizer (NYSE PFE) and Johnson & Johnson (NYSE: JNJ), respectively. The biosimilars were developed by Samsung Bioepis, the joint venture between Samsung BioLogics and US biotech major Biogen (Nasdaq: BIIB).
Under the terms of the deal with Biogen, starting in 2017, Ewopharma will bring Benepali (etancercept) and Flixabi (infliximab) to six countries, Romania, Bulgaria, Croatia, Estonia, Latvia and Lithuania. Benepali and Flixabi are indicated to treat a number of inflammatory diseases, including rheumatoid arthritis, psoriasis, ankylosing spondylitis and inflammatory bowel disease.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biosimilars
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze